Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CVM vs MGTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MGTX Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

MGTX Overall Winner 6-Pillar Tally: CVM 1 – 5 MGTX Matrix Metrics: CVM 2 – 8 MGTX

As of Nov 16, 2026, MeiraGTx Holdings plc (MGTX) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CVM carries a Unified Composite Score of 56.6/100 (HOLD) at $1.59 (23.0x Forward P/E, 0.0% operating margin), whereas MGTX carries 48.0/100 (HOLD) at $8.85 (64.1x Forward P/E, 46.3% operating margin).

  • Composite vs. Pillar Nuance: While CVM currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. MGTX 48.0/100 HOLD), MGTX captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (46.3% vs. 0.0% operating margin) and revenue trajectory (+8608.6% vs. -62.7% YoY).
  • Technical & Structure Timing Caution: CVM is currently in a Breakdown options structure phase (RSI 57.1); meanwhile MGTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CVM vs MGTX
CVM NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.59
+24.22% 1D
Market Cap $20.9M
TTM Revenue $28,558
Forward P/E 23.0x
Beta / 30D Vol 0.65β · 120% Vol
Unified Composite Score
56.6 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 57.1 · SMA20: $1.46 · SMA50: $1.66
MGTX NASDAQ Head-to-Head Winner
MeiraGTx Holdings plc Ordinary Shares
Biological Products, (No Disgnostic Substances)
$8.85
-3.59% 1D
Market Cap $844.2M
TTM Revenue $398M
Forward P/E 64.1x
Beta / 30D Vol 1.65β · 68% Vol
Unified Composite Score
48.0 / 100 HOLD
Tech 48.0 Fund 57.0 Flow 70.0 Mom 58.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.7%), weak momentum, RSI 41
RSI-14: 41.5 · SMA20: $9.39 · SMA50: $10.61

6-Pillar Scorecard Institutional Category Breakdown (CVM 1 – 5 MGTX)

Columns: Metric · CVM · MGTX
1. Valuation Multiples CVM
Forward P/E 23.0x 64.1x
Trailing P/E 23.0x 10.1x
PEG Ratio 1.12x N/M
EV / Revenue N/M 2.0x
2. Growth & Scale MGTX
Revenue Growth (YoY) -62.7% +8608.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $28,558 $398M
Market Cap $20.9M $844.2M
3. Profitability & Quality MGTX
Gross Margin N/A 97.9%
Operating Margin 0.0% 46.3%
Net Profit Margin 0.0% 19.9%
Return on Equity (ROE) -252.5% 72.2%
4. Balance Sheet & Cash Flow MGTX
Cash Generation (TTM) -$17M -$28M
Cash Flow Margin N/A -7.0%
Net Cash / Leverage $6.6M Net Debt (1.24x D/E) $51M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MGTX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile N/A (N/A) 52.9% (3rd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat MGTX
OpEx & R&D Intensity N/A 51.6% of Rev ($205M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CVM (2) vs MGTX (8)
Institutional Metric CVM MGTX Criterion Row Edge
Market Capitalization
Scale
$20.9M $844.2M Larger Scale MGTX
Trailing P/E Ratio
Valuation
23.0x 10.1x Lower Multiple MGTX
Forward P/E Ratio
Valuation
23.0x 64.1x Lower Multiple CVM
Revenue Growth (YoY)
Growth
-62.7% +8608.6% Higher Growth MGTX
Operating Margin (TTM)
Profitability
0.0% 46.3% Higher Margin MGTX
Net Profit Margin
Profitability
0.0% 19.9% Higher Margin MGTX
Return on Equity (ROE)
Capital Efficiency
-252.5% 72.2% Higher ROE MGTX
52-Week Range Position
Momentum
10% ($1–$8) 26% ($7–$15) Stronger Trend MGTX
Beta / 30D Volatility
Risk Regime
0.65β · 120% Vol 1.65β · 68% Vol Lower Realized Risk MGTX
Unified Institutional Score
Composite Signal
56.6 / 100 (HOLD) 48.0 / 100 (HOLD) Higher Composite CVM
Trailing 12M Revenue (USD)
Operating Scale
$28,558 $398M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 97.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.12x PEG · N/M EV/Rev N/M PEG · 2.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$17M ($6.6M Net Debt (1.24x D/E)) -$28M ($51M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MGTX +6.54 pp
CVM: -11.17% · MGTX: -4.63%
3M Horizon CVM +36.29 pp
CVM: +0.0% · MGTX: -36.29%
6M Horizon MGTX +1.71 pp
CVM: -7.56% · MGTX: -5.85%
1Y Horizon MGTX +84.04 pp
CVM: -75.98% · MGTX: +8.06%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CVM Revenue MGTX Revenue CVM Op. Margin MGTX Op. Margin Margin Leader
FY2014 $0M N/A -9721.4% N/A CVM
FY2019 N/A $10M N/A -438.4% MGTX
FY2020 N/A $20M N/A -401.9% MGTX
FY2021 N/A $40M N/A -193.0% MGTX
FY2022 N/A $20M N/A -730.9% MGTX
FY2023 N/A $10M N/A -977.8% MGTX
FY2024 N/A $30M N/A -493.4% MGTX
FY2025 N/A $80M N/A -130.2% MGTX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CVM BREAKDOWN
29d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CVM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MGTX BREAKDOWN
62d in phase · OBV ACCUMULATION
Current IV 52.9%
IV Percentile 3rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact MGTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CVM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $20.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MGTX Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $844.2M market capitalization and 46.3% operating margin.
OpEx & R&D Reinvestment 51.6% of Rev ($205M)
90D Engineering Disclosures 0 Published

Investor FAQ CVM vs MGTX Key Questions & Quantitative Answers

As of Nov 16, 2026, MeiraGTx Holdings plc (MGTX) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CVM carries a Unified Composite Score of 56.6/100 (HOLD) at $1.59 (23.0x Forward P/E, 0.0% operating margin), whereas MGTX carries 48.0/100 (HOLD) at $8.85 (64.1x Forward P/E, 46.3% operating margin). Composite vs. Pillar Nuance: While CVM currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. MGTX 48.0/100 HOLD), MGTX captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (46.3% vs. 0.0% operating margin) and revenue trajectory (+8608.6% vs. -62.7% YoY). Technical & Structure Timing Caution: CVM is currently in a Breakdown options structure phase (RSI 57.1); meanwhile MGTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MGTX leads the Growth & Scale pillar: CVM posts -62.7% YoY revenue growth and +0.0% YoY earnings growth on $28,558 TTM revenue (N/A gross margin, 0.0% operating margin), compared with MGTX at +8608.6% YoY revenue growth and +0.0% YoY earnings growth on $398M TTM revenue (97.9% gross margin, 46.3% operating margin). Across the 8-period historical trajectory (FY2014 to FY2025), CVM cumulative revenue shifted N/A while MGTX shifted +700.0%. In operating R&D and SG&A reinvestment, CVM deploys N/A (0 90-day corporate R&D disclosures) versus 51.6% of Rev ($205M) (0 disclosures) for MGTX.

CVM screens cheaper on headline valuation multiples. CVM trades at 23.0x Forward P/E, 23.0x Trailing P/E, 1.12x PEG, and N/M EV/Revenue (unreported FCF margin), whereas MGTX trades at 64.1x Forward P/E, 10.1x Trailing P/E, N/M PEG, and 2.0x EV/Revenue (-7.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CVM (-252.5% ROE) versus MGTX (72.2% ROE) capital efficiency.

In options market volatility and institutional positioning, CVM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.65β · 120% Vol realized risk). By comparison, MGTX carries 52.9% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.65β · 68% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.